<?xml version="1.0" encoding="UTF-8"?>
<p>We demonstrate that twice‐weekly ixazomib‐Rd offers substantial activity and promising outcomes in NDMM patients but appears to be associated with a somewhat higher toxicity burden than weekly ixazomib‐Rd in this setting. Further investigation of twice‐weekly dosing is potentially warranted to define a subset of patients who are able to tolerate, and benefit from, more intensive therapy.</p>
